Article

Radioprotection Using Iodine-131 for Thyroid Cancer and Hyperthyroidism: A Review

Issa A. Al-Shakhrah

safe handling, cancer treatment
CJON 2008, 12(6), 905-912. DOI: 10.1188/08.CJON.905-912

Radioiodine (iodine-131, or I-131) therapy has been used successfully for thyroid therapy for more than 50 years. Protocols for treatment with I-131 differ from country to country and even from hospital to hospital in the same country. Daily area surveys of hallways, stairwells, and rooms adjacent to isolation rooms must be conducted and documented to ensure that doses to any individuals in unrestricted areas do not exceed 20 mcSv (2 mrem) in one hour. Nursing and housekeeping staffs must realize that once therapy has begun, no items are to be removed from the room unless first cleared by nuclear medicine or radiation safety personnel. With proper education and instructions for patients and their family members, radiation exposure to healthcare professionals and the general public can be minimized. The objectives of this article are to review (a) practical radiation safety concerns associated with hospitalized patients receiving I-131 therapy, (b) preventive measures to minimize potential exposure and contamination problems, and (c) radiation safety precautions and preventive measures to minimize radiation exposure to family members and helpers living with patients receiving outpatient I-131 therapy.

Jump to a section

    References

    Alevizaki, C., Molfetas, M., Samartzis, A., Vlassopoulou, B., Vassilopoulos, C., Rondogianni, P., et al. (2006). Iodine 131 treatment for differentiated thyroid carcinoma in patients with end stage renal failure: Dosimetric, radiation safety, and practical considerations. Hormones, 5(4), 276-287.
    Alexander, C., Bader, J. B., Schaefer, A., Finke, C., & Kirsch, C. M. (1998). Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. Journal of Nuclear Medicine, 39(9), 1551-1554.
    Bajnok, L., Mezosi, E., Nagy, E., Szabo, J., Sztojka, I., Varga, J., et al. (1999). Calculation of the radioiodine dose for the treatment of Graves' hyperthyroidism: Is more than seven-thousand rad target dose necessary? Thyroid, 9(9), 865-869.
    Beierwaltes, W. H. (1987). Radioiodine therapy of thyroid disease. Nuclear Medicine and Biology, 14(3), 177-181.
    Berg, G., Michanek, A., Holmberg, E., & Fink, M. (1996). Iodine-131 treatment of hyperthyroidism: Significance of effective half-life measurements. Journal of Nuclear Medicine, 37(2), 228-232.
    Bushnell, D. L., Boles, M. A., Kaufman, G. E., Wadas, M. A., & Barnes, W. E. (1992). Complications, sequela and dosimetry of iodine-131 therapy for thyroid carcinoma. Journal of Nuclear Medicine, 33(12), 2214-2221.
    Clerc, J., Izembart, M., Dagousset, F., Heshmati, H., Chevalier, A., Leger, A., et al. (1993). Influence of dose selection on absorbed dose in radioiodine treatment of diffuse toxic goiters in patients receiving or not receiving carbimazole. Journal of Nuclear Medicine, 34(3), 387-393.
    Culver, C., Dworkin, H. J., & Forsaith, A. (1993). Disposal of small quantities of radioactive materials in local landfills: Problems and solutions. Journal of Nuclear Medicine, 34(2), 349-350.
    De Bruin, T., Croon, C., de Klerk, J., & van Isselt, J. (1994). Standardized radioiodine therapy in Graves' disease: The persistent effect of thyroid weight and radioiodine uptake on outcome. Journal of Internal Medicine, 236(5), 507-513.
    Di Martino, F., Traino, A., Brill, A., Stabin, M., & Lazzer, M. (2002). A theoretical model for prescription of the patient-specific therapeutic activity for radioiodine therapy of Graves' disease. Physics in Medicine and Biology, 47(9), 1493-1499.
    Dottorini, M. E., Lomuscio, G., Mazzucchelli, L., Vignati, A., & Colombo, L. (1995). Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. Journal of Nuclear Medicine, 36(1), 21-27.
    European Communities. (1997). Council directive 97/43/Euratom of 30 June 1997 on health protection of individuals against the dangers of ionising radiation in relation to medical exposure, and repealing directive 84/466/Euratom. Official Journal of the European Communities. Retrieved October 24, 2008, from http://ec.europa.eu/energy/nuclear/radioprotection/doc/legislation/9743_en.pdf
    Hackett, M. T., Perdikaris, N., & Ruffin, T. T. (1995). Additional radiation safety concerns involving sodium iodide-131 capsules. Journal of Nuclear Medicine Technology, 23, 289-290.
    Hurley, J. R., & Becker, D. V. (1988). Treatment of thyroid carcinoma with radioiodine. In A. Gottschalk, P. B. Hoffer, E. J. Potchen, & H. J. Berger (Eds.), Diagnostic nuclear medicine (vol. 2, 2nd ed.). Baltimore: Williams and Wilkins.
    International Commission on Radiological Protection. (1977). Recommendations of the International Commission on Radiological Protection [ICRP Publication 26]. Annals of the ICRP, 1(3).
    International Commission on Radiological Protection. (1991). 1990 recommendations of the International Commission on Radiological Protection [ICRP Publication 60]. Annals of the ICRP, 21(1-3).
    Jonsson, H., & Mattsson, S. (2004). Excess radiation absorbed doses from non-optimised radioiodine treatment of hyperthyroidism. Radiation Protection Dosimetry, 108(2), 107-114.
    Leeper, R. D. (1982). Controversies in the treatment of thyroid cancer: The New York Memorial Hospital approach. Thyroid Today, 5, 1-4.
    Leung, S. F., Law, M. W., & Ho, S. K. (1992). Efficacy of low-dose iodine-131 ablation of post-operative thyroid remnants: A study of 69 cases. British Journal of Radiology, 65(778), 905-909.
    Maxon, H. R., Thomas, S. R., Hertzberg, V. S., Kereiakes, J. G., Chen, I. W., Sperling, M. I., et al. (1983). Relation between effective radiationdose and outcome of radioiodine therapy for thyroid cancer. New England Journal of Medicine, 309(16), 937-941.
    Maxon, H. R., Thomas, S. R., & Samaratunga, R. C. (1997). Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Thyroid, 7(2), 183-187.
    McCowen, K. D., Adler, R. A., Ghaed, N., Verdon, T., & Hofeldt, F. D. (1976). Low dose radioiodide thyroid ablation in postsurgical patients with thyroid cancer. American Journal of Medicine, 61(1), 52-58.
    Modarresifar, H., Almodovar, S., Bass, W. B., & Ojha, B. (2007). Radiation safety protocol for high dose 131I therapy of thyroid carcinoma in patients on homodialysis for chronic renal failure. Health Physics, 92(2, Suppl.), S45-S49.
    Office of Nuclear Regulatory Research. (1997). U. S. Nuclear Regulatory Commission regulatory guide 8.39, release of patients administered radioactive materials. Washington, DC: Nuclear Regulatory Commission.
    Office of Nuclear Regulatory Research. (2000a). The code of federal regulations [Title 10, Energy; Part 20, Standards for protection against radiation; Section 1301, Dose limits for individual members of the public]. Washington, DC: Nuclear Regulatory Commission.
    Office of Nuclear Regulatory Research. (2000b). The code of federal regulations [Title 10, Energy; Part 35, Medical use of byproduct material; Section 75, Release of individuals containing radiopharmaceuticals or permanent implants]. Washington, DC: Nuclear Regulatory Commission.
    Office of Nuclear Regulatory Research. (2000c). The code of federal regulations [Title 10, Energy; Part 35, Medical use of byproduct material; Section 92, Decay-in-storage]. Washington, DC: Nuclear Regulatory Commission.
    Office of Nuclear Regulatory Research. (2000d). The code of federal regulations [Title 10, Energy; Part 35, Medical use of byproduct material; Section 315, Safety precautions.] Washington, DC: Nuclear Regulatory Commission.
    Pant, G. S., Sharma, S. K., Bal, C. S., Kumar, R., & Rath, G. K. (2006). Radiation dose to family members of hyperthyroidism and thyroid cancer patients treated with 131I. Radiation Protection Dosimetry, 118(1), 22-27.
    Panzegrau, B., Gordon, L., & Goudy, G. H. (2005). Outpatient therapeutic 131I for thyroid cancer. Journal of Nuclear Medicine Technology, 33(1), 28-30.
    Parthasarathy, K. L., & Crawford, E. S. (2002). Treatment of thyroid carcinoma: Emphasis on high-dose 131I outpatient therapy. Journal of Nuclear Medicine Technology, 30(4), 165-171.
    Peters, H., Fischer, C., Bogner, U., Reiners, C., & Schleusener, H. (1995). Radioiodine therapy of Graves' hyperthyroidism: Standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study. European Journal of Clinical Investigation, 25(3), 186-193.
    Phan, T., Ling, M., & Wasnich, R. (1987). Practical nuclear pharmacy (3rd ed.). Honolulu, Hawaii: Banyan Press.
    Rajashekharrao, B., & Nair, N. (1991). Thyroidal absorbed dose from a standard five-millicurie iodine-131 (185 MBq) dose for thyrotoxicosis: Cure can occur with less than the conventional 7000 rads. Journal of Nuclear Medicine, 32(2), 364-365.
    Reinhardt, M., Brink, I., Joe, A., von Mallek, D., Ezziddin, S., Palmedo, H., et al. (2002). Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: Effect of pre-treatment thyroid volume on clinical outcome. European Journal of Nuclear Medicine, 29(9), 1118-1124.
    Reston, V. A. (1997). Guidelines for patients receiving radioiodine treatment [pamphlet]. Reston, VA: American Society of Nuclear Medicine, Inc.
    Seilini, S. M., & Marinelli, L. D. (1945). Therapeutic effect of radioactive iodine on adenocarcinoma of the thyroid with functioning metastases [Abstract]. Bulletin of the New York Academy of Medicine, 21, 440.
    Sgouros, G. (1993). Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations. Journal of Nuclear Medicine, 34(4), 689-694.
    Shapiro, B. (1993). Optimization of radioiodine therapy of thyrotoxicosis: What have we learned after 50 years? Journal of Nuclear Medicine, 34(10), 1638-1641.
    Siegel, J. A., Wessels, B. W., Watson, E. E., Stabin, M. G., Vriesendorp, H. M., Bradley, E. W., et al. (1990). Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody, Immunoconjugates, and Radiopharmaceuticals, 3(2), 213-233.
    Solans, R., Bosch, J. A., Galofre, P., Porta, F., Rosello, J., Selva-O'Callagan, A., et al. (2001). Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. Journal of Nuclear Medicine, 42(5), 738-743.
    Swedish Radiation Protection Authority. (2000). The Swedish Radiation Protection Institute's regulations and general advice on nuclear medicine [SSI FS 2000:3]. Retrieved October 24, 2008, from http://www.stralsakerhetsmyndigheten.se/Global/Publikationer/F%C3%B6rfattning/Str%C3%A5lskydd/2000/ssifs-2000-3e.pdf
    Thompson, M. A. (2001). Radiation safety precautions in the management of the hospitalized (131)I therapy patient. Journal of Nuclear Medicine Technology, 29(2), 61-66.
    Traino, A., Di Martino, F., Lazzeri, M., & Stabin, M. (2000). Influence of thyroid volume reduction on calculated dose in radioiodine therapy of Graves' hyperthyroidism. Physics in Medicine and Biology, 45(1), 121-129.
    Traino, A. C., Di Martino, F., Boni, G., Mariani, G., & Lazzeri, M. (2004). A minimally invasive method to evaluate 131I kinetics in blood. Radiation Protection Dosimetry, 109(3), 249-252.
    United Nations Scientific Committee on the Effects of Atomic Radiation. (n.d.). Report of the United Nations Scientific Committee on the Effects of Atomic Radiation to the General Assembly. Retrieved November 13, 2008, from http://www.unscear.org/docs/reports/gareport.pdf
    Van Nostrand, D., Neutze, J., & Atkins, F. (1986). Side effects of "rational dose" iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. Journal of Nuclear Medicine, 27(10), 1519-1527.
    Varma, V. M., Beierwaltes, W. H., Nofal, M. M., Nishiyama, R. H., & Copp, J. E. (1970). Treatment of thyroid cancer: Death rates after surgery and after surgery followed by sodium iodide I-131. JAMA, 214(8), 1437-1442.
    Willemsen, U. F., Knesewitsch, P., Kreisig, T., Pickardt, C. R., & Kirsch, C. M. (1993). Functional results of radioiodine therapy with a 300-Gy absorbed dose in Graves' disease. European Journal of Nuclear Medicine, 20(11), 1051-1055.